Poolbeg Pharma list of upcoming events

Poolbeg Pharma

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has announced that its management and business development team will be attending and presenting at a number upcoming partnering and investor events from October 2022 to January 2023.

Partnering events

BIO-Europe from 24-26 October 2022 at Leipzig Messe, Leipzig, Germany 04356
Jefferies London Healthcare Conference from 15-17 November 2022 in London
JP Morgan 41st Annual Healthcare Conference from 9-12 January 2023 at the Westin St. Francis Hotel, San Francisco, CA

Investor events

London South East Webinar (virtual) on 8 November 2022. Register here
LSX Investival ShowcaseTM on 14 November 2022 at Old Billingsgate, London EC3R 6DX. Poolbeg CEO, Jeremy Skillington, will present at 14:15 on Stage 4: Biotech Late Growth. Register here

Event details may be subject to change – further information and updates are available on the Poolbeg Pharma website here.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs.

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs.

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy.

Poolbeg Pharma targets severe flu and cytokine storms

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy.

POLB 001 targets deadly cytokine storms in cancer therapy

Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes.

Search

Search